肝片吸蟲病市場：依藥物、通路和地區分類

Fascioliasis Market, By Drug, By Distribution Channel, And by Region

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，到 2026 年，肝片吸蟲病市場規模將達到 4.13 億美元，預計到 2033 年將達到 5.704 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 4.7%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	4.13億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.70%	2033年市場規模預測：	5.704億美元

肝片吸蟲感染疾病通常由肝片吸蟲（俗稱「普通肝吸蟲」或「綿羊肝吸蟲」）引起。肝片吸蟲病由兩種肝片吸蟲引起：主要種類是肝片吸蟲，另一種是近緣種巨片吸蟲。巨片吸蟲也能感染人類。巨片吸蟲分佈於一些熱帶地區，例如澳洲和中國。在綿羊和牛的養殖區，肝吸蟲病較為常見。人類感染的途徑包括誤食生西洋菜或其他受污染的淡水植物，或飲用受污染的水。其他感染途徑還包括食用用受污染的水清洗或灌溉的蔬菜。避免食用生西洋菜或其他水生植物，尤其是流行地區牧場種植的植物，可以預防肝吸蟲病感染。感染初期，由於幼蟲從腸道遷移至腹腔和肝臟，有些人可能會感到不適。肝片吸蟲病是可以治療和預防的。

市場動態

預計在預測期內，採用非個人化策略（例如美國食品藥物管理局(FDA) 的產品核可）將推動全球肝片吸蟲病市場成長。例如，2019 年 2 月，食品藥物管理局諾華宣布，三氯苯達唑 (Egaten) 已獲得 FDA 批准，用於治療 6 歲及以上患者的肝片吸蟲病。三氯苯達唑在美國的核准預計將促進該藥物在流行國家的許可和進口，從而確保在需要時能夠獲得充足的藥物供應。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球肝片吸蟲病市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份全球肝片吸蟲病市場報告旨在為行業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用全球肝片吸蟲病市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

Novartis AG
AMGIS Lifescience Ltd.
Romark
- Company Highlight
AbbVie Inc.
Merck KGaA
AdvaCare Pharma
Intas Pharmaceuticals Ltd.
Procyon Life Sciences
Adroit Pharmachem Pvt Ltd.
Sun Pharmaceutical Industries Ltd.
RV Lifesciences Limited
Grampus Laboratories
Janssen Pharmaceuticals, Inc.

第8章

調查方法
關於本公司

簡介目錄

Product Code: CMI5596

Fascioliasis Market is estimated to be valued at USD 413.0 Mn in 2026 and is expected to reach USD 570.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 413.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.70%	2033 Value Projection:	USD 570.4 Mn

Fascioliasis is an infectious disease usually caused by Fasciola hepatica, also called as the common liver fluke or the sheep liver fluke. Fascioliasis is caused by two fasciola species, the main species Fasciola hepatica, and another related species Fasciola gigantica, which also can infect people. Fasciola gigantica has been found in some tropical areas such as Australia, China. Fascioliasis is found where sheep or cattle are reared. People are infected with Fasciola when the parasite is accidentally ingested (swallowed) through raw watercress or other contaminated freshwater plants, and also by drinking contaminated water. Other ways include by eating vegetables that were washed or irrigated with contaminated water. Fasciola infection can be prevented by not eating raw watercress and other water plants, especially from endemic grazing areas. Some people feel sick during the early stage of infection, while immature flukes migrate from the intestine through the abdominal cavity and liver. Fasciola infection is both treatable and preventable.

Market Dynamics

Increasing adoption of inorganic strategies such as product approvals by the U.S. Food and Drug Administration is expected to drive the global fascioliasis market growth over the forecast period. For instance, in February 2019, Novartis AG, a pharmaceutical company, announced that they had received an approval from the U.S.Food and Drug Administration for triclabendazole (Egaten) for the treatment of fascioliasis in patients aged 6 years and older. The approval of triclabendazole in the U.S. is expected to facilitate drug licensing and import to endemic countries, to provide a help for the sufficient availability of the drug when needed.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global fascioliasis market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, AMGIS Lifescience Ltd., Romark, AbbVie Inc., Merck KGaA, AdvaCare Pharma, Intas Pharmaceuticals Ltd., Procyon Life Sciences, Adroit Pharmachem Pvt Ltd., Sun Pharmaceutical Industries Ltd., RV Lifesciences Limited, Grampus Laboratories, and Janssen Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global fascioliasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fascioliasis market

Detailed Segmentation:

Global Fascioliasis Market, By Drug (Revenue, USD Mn, 2021 - 2033)
Triclabendazole
Albendazole
Nitazoxanide
Global Fascioliasis Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Fascioliasis Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Novartis AG*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
AMGIS Lifescience Ltd.
Romark
AbbVie Inc.
Merck KGaA
AdvaCare Pharma
Intas Pharmaceuticals Ltd.
Procyon Life Sciences
Adroit Pharmachem Pvt Ltd.
Sun Pharmaceutical Industries Ltd.
RV Lifesciences Limited
Grampus Laboratories
Janssen Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Regulatory Guidelines
Product launches
Key Development
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Fascioliasis Market, By Drug, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Triclabendazole
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Albendazole
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Nitazoxanide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Fascioliasis Market, By Distribution Channel, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Fascioliasis Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AMGIS Lifescience Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Romark
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AdvaCare Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Procyon Life Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Adroit Pharmachem Pvt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
RV Lifesciences Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Grampus Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Janssen Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies